Fig. 4: GT-02897 degrades CDK9 and suppresses tumor in CTCL xenograft model.

a–c NSG mice were subcutaneously injected with Hut78 cells (8 × 10⁶ cells for each mouse) and randomly divided into two groups receiving intraperitoneal injection of Vehicle or 23 (GT-02897) (n = 4). Tumor volumes were measured at different time points (a). At 14 days after subcutaneous injection, tumors were harvested and weighed (b), followed by IHC staining of human CDK9 (c). P value was calculated by two-tailed Student’s t-test. d, e NSG mice were subcutaneously injected with Hut78 cells (8 × 10⁶ cells for each mouse) and randomly divided into two groups receiving subcutaneously injection of Vehicle or 23 (GT-02897) (n = 5). Tumor volumes were measured at different time points (d) and survival curves were shown (e). P value of tumor volumes was calculated by two-tailed Student’s t-test, P value of survival curve was calculated by log-rank test. f–h NSG mice were subcutaneously injected with Hut78 cells introduced with shNC, shCDK9-1 or shCDK9-2 (8 × 10⁶ cells for each mouse) and treated with 23 (GT-02897) (n = 6). Tumor volumes were measured at different time points (f). At 12 days after subcutaneous injection, tumors were harvested and weighed (g, h). P value was calculated by two-tailed Student’s t-test. Data are presented as mean ± SEM. Source data are provided as a Source Data file.